BELLICUM PHARMACEUTICALS INC (BLCM) Stock Price, Quote, News and Overview
NASDAQ:BLCM - Nasdaq - US0794814048 - Common Stock - Currency: USD
BLCM Quote, Performance and Key Statistics
0.622
-0.07 (-9.72%)
The current stock price of BLCM is 0.622 USD. In the past month the price increased by 64.03%. In the past year, price decreased by -47.29%.
BLCM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About BLCM
Company Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2014-12-18. The firm is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. The company has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.
Company Info
BELLICUM PHARMACEUTICALS INC
3730 Kirby Drive, Suite 1200
Houston TEXAS 77098 US
CEO: Richard A. Fair
Employees: 13
Company Website: https://www.bellicum.com/
Phone: 18323841100.0
BELLICUM PHARMACEUTICALS INC / BLCM FAQ
What is the stock price of BELLICUM PHARMACEUTICALS INC today?
The current stock price of BLCM is 0.622 USD. The price decreased by -9.72% in the last trading session.
What is the ticker symbol for BELLICUM PHARMACEUTICALS INC stock?
The exchange symbol of BELLICUM PHARMACEUTICALS INC is BLCM and it is listed on the Nasdaq exchange.
On which exchange is BLCM stock listed?
BLCM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BELLICUM PHARMACEUTICALS INC stock?
6 analysts have analysed BLCM and the average price target is 5.1 USD. This implies a price increase of 719.94% is expected in the next year compared to the current price of 0.622. Check the BELLICUM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BELLICUM PHARMACEUTICALS INC worth?
BELLICUM PHARMACEUTICALS INC (BLCM) has a market capitalization of 5.91M USD. This makes BLCM a Nano Cap stock.
How many employees does BELLICUM PHARMACEUTICALS INC have?
BELLICUM PHARMACEUTICALS INC (BLCM) currently has 13 employees.
What are the support and resistance levels for BELLICUM PHARMACEUTICALS INC (BLCM) stock?
BELLICUM PHARMACEUTICALS INC (BLCM) has a resistance level at 0.63. Check the full technical report for a detailed analysis of BLCM support and resistance levels.
Is BELLICUM PHARMACEUTICALS INC (BLCM) expected to grow?
The Revenue of BELLICUM PHARMACEUTICALS INC (BLCM) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BLCM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BELLICUM PHARMACEUTICALS INC (BLCM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BLCM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BLCM, evaluating the profitability, health, valuation and growth aspects
- BELLICUM PHARMACEUTICALS INC (BLCM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BELLICUM PHARMACEUTICALS INC (BLCM) Sales and EPS estimates to see what analysts future expectations are.
- BELLICUM PHARMACEUTICALS INC (BLCM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BELLICUM PHARMACEUTICALS INC (BLCM) Insider and Institutional Ownership to learn about the owners and their transactions.
- BELLICUM PHARMACEUTICALS INC (BLCM) Stock Chart to make your own analysis
- BELLICUM PHARMACEUTICALS INC (BLCM) Latest news and press-releases to stay up to date.
Does BELLICUM PHARMACEUTICALS INC (BLCM) stock pay dividends?
BLCM does not pay a dividend.
When does BELLICUM PHARMACEUTICALS INC (BLCM) report earnings?
BELLICUM PHARMACEUTICALS INC (BLCM) will report earnings on 2023-08-09.
What is the Price/Earnings (PE) ratio of BELLICUM PHARMACEUTICALS INC (BLCM)?
BELLICUM PHARMACEUTICALS INC (BLCM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.82).
BLCM Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLCM. When comparing the yearly performance of all stocks, BLCM is a bad performer in the overall market: 90.07% of all stocks are doing better.
BLCM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLCM. BLCM has a bad profitability rating. Also its financial health evaluation is rather negative.
BLCM Financial Highlights
Over the last trailing twelve months BLCM reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS decreased by -183.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
BLCM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to BLCM. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 38.37% and a revenue growth -100% for BLCM